Preservation of Vision in GA in ARCHER Trial Continues Evaluation in ARCHER II

The first known clinically meaningful preservation of vision in GA.

By: Priya Vakharia, MD, Michael A. Singer, MD

Retinal Physician June 20, 2025

1

The ARCHER trial evaluated ANX007 for geographic atrophy, showing promising secondary outcomes in visual acuity despite not meeting primary endpoints.
2

Patients receiving ANX007 had significantly lower rates of 15-letter loss of vision compared to the sham group, indicating potential vision preservation.
3

The number needed to treat with ANX007 to prevent one patient from significant vision loss is 7, which is favorable compared to common cardiovascular medications.
4

The ongoing phase 3 ARCHER II trial focuses on visual acuity as a primary endpoint, marking a shift in GA treatment evaluation.
5

ANX007 demonstrated approximately 60% protection of photoreceptors in the fovea, suggesting a novel approach to assessing GA treatment efficacy.

1